NCT04751422
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must have underwent radiofrequency ablation with cement augmentation at MD Anderson Cancer Center
Exclusions: 
https://ClinicalTrials.gov/show/NCT04751422